NCT03914612 · OUTCOME

Overall Survival (OS)

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · Source last updated 2026-07-31

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Time from study entry to time of death or the date of last contact, assessed up to 5 years

What was measured

Overall Survival (OS). This endpoint will be assessed by Kaplan-Meier.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2029-04
denom Units Selected: Participants
description: Overall Survival (OS). This endpoint will be assessed by Kaplan-Meier.
reporting Status: NOT_POSTED
time Frame: Time from study entry to time of death or the date of last contact, assessed up to 5 years
title: Overall Survival (OS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice